Iranian National Thalassaemia Screening Programme

Thalassemia premarital screening program was started from 1997 in Iran The thalassemia prevention program in Iran is based upon premarital screening of thalassaemia couples carriers in order to encourage them to participate in counseling and prenatal diagnosis PND In this program red cell indices are checked

Samavat A Modell B Iranian national thalassaemia screening programme BMJ 2004 329 11347 doi 101136bmj32974751134 pmid 15539666 Loukopoulos D Current status of thalassaemia and the sickle cell syndromes in Greece Semin Hematol 1996 33 7686 pmid 8714587

Jun 23 2010 Thalassaemia carrier screening has been included as part of an existing mandatory premarital blood test in Iran since 1991 22 23 24 This form of mandatory premarital thalassaemia screening also began in the Gaza Strip in 2000 9 and in Saudi Arabia in 2003 20 Carrier couples receive advice on the options available to them one of which is

May 19 2016 THE NATIONAL THALASSAEMIA SCREENING PROGRAMME 31 OBJECTIVES 311 General objective To identify carriers of thalassaemia in order to assess the risk of an individual having a affected child and to provide information on the options available to avoid such eventuality 312 Specific objectives a To strengthen screening services for

Thalassaemia major is the most common hereditary disease in Iran The premarital screening programme for thalassaemia major prevention which started in 1995 1 is one of the most successful health programmes in Iran resulting in a significantly reduced incidence of new cases over the last two decades 23 Many new cases are associated with marriages that began before the implementation

Iranian national thalassaemia screening programme Ashraf Samavat Bernadette Modell Irans experience shows that genetic screening can be successful in lower resource countries and also provides some lessons for high resource nations Progress in controlling communicable diseases increases the relative importance of non

Premarital haemoglobinopathy screening should not be mandatory in a nonprevalent region of a prevalent country as part of a national control programme If screening is mandatory it should be performed by total blood count or enzymelinked immunosorbent assay which are simple rapid and less expensive than HPLC

We reviewed the medical and economic burden of thalassaemia major with emphasis on prenatal diagnosis for disease prevention as the most economic health care policy approach The current programme in the Islamic Republic of Iran screens couples just before marriage identifies carriers and refers them for genetic counselling

work from each of the 11 national programmes For example PHE Screenings national programme team pages 14 and 15 has worked closely with local NHS screening providers to identify barriers to women accessing sickle cell and thalassaemia screening early in pregnancy This has resulted in national and local changes to

The first screening program for prevention of Thalassaemia was initiated in 1991 in the Fars province located in the south of Iran The next major screening program formed in 1995 by the joint contribution and efforts of the Iranian Thalassaemia Society and the Iranian Blood Transfusion Organization where all the highschool students in Tehran

Thalassaemia is one of the most common Mendelian disorders in Mediterranean area Iran has about 26000 Thalassaemic patients so it is one of the most affected countries The aim of this study was to evaluate the screening program and cost analysis

Jan 01 2013 Sickle cell and thalassaemia SCT screening programme overview KPI data reports are available for all 11 national screening programmes Requests for screening

national charities which represent people affected by thalassaemia and sickle cell disorders respectively Both Societies collaborate closely with the NHS Sickle Cell and Thalassaemia Screening Programme NHSSCTSP in areas such as public outreach patient engagement media support social research lobbying campaigning and policy

The critical issue in the screening process is the differential diagnosis of individuals with the phenotype of normal HbA 2 thalassemia type 2 low MCV low MCH normal or borderline HbA 2 which may result from iron deficiency thalassemia thalassemia double heterozygosity for and thalassemia or mild thalassemia

Thalassemia premarital screening program was started from 1997 in Iran The thalassemia prevention program in Iran is based upon premarital screening of thalassaemia couples carriers in order

Learning from low income countries Thalassaemia screening in Iran provides evidence for programme in Lancashire Article PDF Available in BMJ online 3307489478 discussion 479

A novel mutation of the bglobin gene promoter 2102 CA and pitfalls in family screening Am J Hematol 2007 8210881090 Samavat A Modell B Iranian national thalassaemia screening programme BMJ 200432911347 Christianson A Streetly A Darr A Lessons from thalassaemia screening in Iran BMJ 2004 329747511157

Screening for Thalassemia in Iran The Islamic Revolution in Iran in the 1970s led to the abandonment of the program of family planning established under the Shah The population surged reaching an annual increase of 39

Background Beta thalassemia is a common health problem in Iran especially in Northern provinces Premarital screening for thalassemia is compulsory in Iran and identification of the carriers is based on primary CBC Cell Blood Count and hemoglobin electrophoresis Silent mutations on globin gene have borderline or normal hematological indices that cannot

Samavat A Modell B Iranian national thalassaemia screening programme BMJ 2004329747511347 Hesketh T Getting married in China pass the medical first BMJ 200332673832779 Ginsberg G Tulchinsky T Filon D et al Costbenefit analysis of a national thalassaemia prevention programme in Israel J Med Screen 1998531206

A primary care led genetic screening programme for thalassaemia in Iran has proved feasible acceptable and effective Samavat and Modell describe the development of Irans national programme which has resulted in a 70 reduction in expected births of affected provides a model for other countries including developed countries seeking to implement comprehensive equitable

Backgroundthalassaemia is a preventable has about 20000 homozygote thalassaemia patients and 3750000 carriers Objective To assess the 10year results of the screening programme which has been operating in Southern Iran since 1995 Methods All couples wanting to marry were required to be checked for thalassaemia by their red blood cell indices in

Mar 02 2020 This report presents screening data for the NHS sickle cell and thalassaemia SCT screening programme for the financial year 1 April 2017 to

Mar 01 2019 These documents present the national screening standards for the NHS sickle cell and thalassaemia SCT screening most recent standards apply to

Jun 23 2010 Samavat A Modell B Iranian national thalassaemia screening programme BMJ 2004 32911341137 Europe PMC free article Google Scholar Angastiniotis MA Hadjiminas MG Prevention of thalassaemia in Cyprus Lancet 1981 1369371 Google Scholar Cowan RS Moving up the slippery slope mandated genetic screening on Cyprus

Thalassemia screening program in Iran is a wellcoordinated national approach in which screening is integrated with services for patients 76 Genetic Epidemiology Hematological and Clinical

Iranian national thalassaemia screening programme By Ashraf Samavat and Bernadette Modell Abstract Irans experience shows that genetic screening can be successful in lower resource countries and also provides some lessons for high resource nation Topics Primary Care